184 related articles for article (PubMed ID: 16754747)
1. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes.
Finnson KW; Tam BY; Liu K; Marcoux A; Lepage P; Roy S; Bizet AA; Philip A
FASEB J; 2006 Jul; 20(9):1525-7. PubMed ID: 16754747
[TBL] [Abstract][Full Text] [Related]
2. CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis.
Litvinov IV; Bizet AA; Binamer Y; Jones DA; Sasseville D; Philip A
Exp Dermatol; 2011 Aug; 20(8):627-32. PubMed ID: 21539622
[TBL] [Abstract][Full Text] [Related]
3. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.
Hagiwara S; Murakumo Y; Mii S; Shigetomi T; Yamamoto N; Furue H; Ueda M; Takahashi M
Oncogene; 2010 Apr; 29(15):2181-91. PubMed ID: 20101215
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD109 binds TGF-β and antagonizes TGF-β signalling and responses.
Li C; Hancock MA; Sehgal P; Zhou S; Reinhardt DP; Philip A
Biochem J; 2016 Mar; 473(5):537-47. PubMed ID: 26621871
[TBL] [Abstract][Full Text] [Related]
5. CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells.
Zhang JM; Murakumo Y; Hagiwara S; Jiang P; Mii S; Kalyoncu E; Saito S; Suzuki C; Sakurai Y; Numata Y; Yamamoto T; Takahashi M
Biochem Biophys Res Commun; 2015 Apr; 459(2):252-258. PubMed ID: 25724945
[TBL] [Abstract][Full Text] [Related]
6. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function.
Bizet AA; Tran-Khanh N; Saksena A; Liu K; Buschmann MD; Philip A
J Cell Biochem; 2012 Jan; 113(1):238-46. PubMed ID: 21898545
[TBL] [Abstract][Full Text] [Related]
7. Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-beta signaling in human keratinocytes.
Tam BY; Finnson KW; Philip A
J Biol Chem; 2003 Dec; 278(49):49610-7. PubMed ID: 14504277
[TBL] [Abstract][Full Text] [Related]
8. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors.
Bizet AA; Liu K; Tran-Khanh N; Saksena A; Vorstenbosch J; Finnson KW; Buschmann MD; Philip A
Biochim Biophys Acta; 2011 May; 1813(5):742-53. PubMed ID: 21295082
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a 150 kDa accessory receptor for TGF-beta 1 on keratinocytes: direct evidence for a GPI anchor and ligand binding of the released form.
Tam BY; Larouche D; Germain L; Hooper NM; Philip A
J Cell Biochem; 2001 Aug 21-Sep 5; 83(3):494-507. PubMed ID: 11596117
[TBL] [Abstract][Full Text] [Related]
10. CD109: a multifunctional GPI-anchored protein with key roles in tumor progression and physiological homeostasis.
Mii S; Enomoto A; Shiraki Y; Taki T; Murakumo Y; Takahashi M
Pathol Int; 2019 May; 69(5):249-259. PubMed ID: 31219232
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CD109 in the Epidermis Differentially Regulates ALK1 Versus ALK5 Signaling and Modulates Extracellular Matrix Synthesis in the Skin.
Vorstenbosch J; Nguyen CM; Zhou S; Seo YJ; Siblini A; Finnson KW; Bizet AA; Tran SD; Philip A
J Invest Dermatol; 2017 Mar; 137(3):641-649. PubMed ID: 27866969
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-beta binding proteins.
Tam BY; Philip A
J Cell Physiol; 1998 Sep; 176(3):553-64. PubMed ID: 9699508
[TBL] [Abstract][Full Text] [Related]
13. The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β.
Tanabe M; Hosokawa K; Nguyen MAT; Nakagawa N; Maruyama K; Tsuji N; Urushihara R; Espinoza L; Elbadry MI; Mohiuddin M; Katagiri T; Ono M; Fujiwara H; Chonabayashi K; Yoshida Y; Yamazaki H; Hirao A; Nakao S
Leukemia; 2022 Mar; 36(3):847-855. PubMed ID: 34743190
[TBL] [Abstract][Full Text] [Related]
14. Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis.
Liu XX; Feng AP; He YM; Li Y; Wu Y; Lian X; Hu F; Li JW; Tu YT; Chen SJ
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):132-136. PubMed ID: 26838754
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Paterson IC; Matthews JB; Huntley S; Robinson CM; Fahey M; Parkinson EK; Prime SS
J Pathol; 2001 Apr; 193(4):458-67. PubMed ID: 11276004
[TBL] [Abstract][Full Text] [Related]
16. CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family.
Solomon KR; Sharma P; Chan M; Morrison PT; Finberg RW
Gene; 2004 Mar; 327(2):171-83. PubMed ID: 14980714
[TBL] [Abstract][Full Text] [Related]
17. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
[TBL] [Abstract][Full Text] [Related]
18. CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-β signaling.
Taki T; Shiraki Y; Enomoto A; Weng L; Chen C; Asai N; Murakumo Y; Yokoi K; Takahashi M; Mii S
Cancer Sci; 2020 Dec; 111(12):4616-4628. PubMed ID: 33007133
[TBL] [Abstract][Full Text] [Related]
19. CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
Yokoyama M; Ichinoe M; Okina S; Sakurai Y; Nakada N; Yanagisawa N; Jiang SX; Numata Y; Umezawa A; Miyazaki K; Higashihara M; Murakumo Y
Int J Hematol; 2017 May; 105(5):614-622. PubMed ID: 28032275
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
